MA53069B1 - Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer - Google Patents

Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer

Info

Publication number
MA53069B1
MA53069B1 MA53069A MA53069A MA53069B1 MA 53069 B1 MA53069 B1 MA 53069B1 MA 53069 A MA53069 A MA 53069A MA 53069 A MA53069 A MA 53069A MA 53069 B1 MA53069 B1 MA 53069B1
Authority
MA
Morocco
Prior art keywords
antibody
igf
treatment
cancer
relates
Prior art date
Application number
MA53069A
Other languages
English (en)
Other versions
MA53069A1 (fr
Inventor
Charlotte Beau-Larvor
Liliane Goetsch
Matthieu Broussas
Thierry Champion
Alain Robert
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MA53069A1 publication Critical patent/MA53069A1/fr
Publication of MA53069B1 publication Critical patent/MA53069B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

La présente invention concerne un anticorps, en particulier un anticorps monoclonal, pouvant se lier spécifiquement à igf-1r, ainsi que des séquences d'acides aminés et d'acides nucléiques codant pour cet anticorps. Dans un aspect, l'invention concerne un anticorps, ou un fragment de liaison d'antigène de celui-ci, pouvant se lier à l'igf-1r et, par l'induction d'une internalisation d'igf-1r, étant internalisé dans la cellule. L'invention concerne également l'utilisation de cet anticorps en tant que véhicule d'adressage conjugué à d'autres composés anticancéreux, tels que des toxines, des radioéléments ou des médicaments, et l'utilisation de ceux-ci pour le traitement de certains cancers.
MA53069A 2014-04-25 2015-04-27 Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer MA53069B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461984160P 2014-04-25 2014-04-25
PCT/EP2015/059050 WO2015162292A1 (fr) 2014-04-25 2015-04-27 Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer

Publications (2)

Publication Number Publication Date
MA53069A1 MA53069A1 (fr) 2021-10-29
MA53069B1 true MA53069B1 (fr) 2022-04-29

Family

ID=53373391

Family Applications (2)

Application Number Title Priority Date Filing Date
MA39378A MA39378B2 (fr) 2014-04-25 2015-04-27 Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer
MA53069A MA53069B1 (fr) 2014-04-25 2015-04-27 Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA39378A MA39378B2 (fr) 2014-04-25 2015-04-27 Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer

Country Status (29)

Country Link
US (2) US10202458B2 (fr)
EP (2) EP3783033A1 (fr)
JP (2) JP6835591B2 (fr)
KR (3) KR20220018620A (fr)
CN (2) CN106459204B (fr)
AU (1) AU2015250760C1 (fr)
BR (1) BR112016024575B1 (fr)
CA (1) CA2946795C (fr)
CY (1) CY1123743T1 (fr)
DK (1) DK3134438T3 (fr)
ES (1) ES2841249T3 (fr)
HR (1) HRP20202047T1 (fr)
HU (1) HUE052223T2 (fr)
IL (2) IL248357B (fr)
LT (1) LT3134438T (fr)
MA (2) MA39378B2 (fr)
MX (2) MX2016014000A (fr)
MY (1) MY182444A (fr)
NZ (1) NZ725423A (fr)
PL (1) PL3134438T3 (fr)
PT (1) PT3134438T (fr)
RS (1) RS61379B1 (fr)
RU (1) RU2698977C2 (fr)
SA (1) SA516380131B1 (fr)
SI (1) SI3134438T1 (fr)
TN (1) TN2016000445A1 (fr)
UA (1) UA122390C2 (fr)
WO (1) WO2015162292A1 (fr)
ZA (1) ZA201607095B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3134124T3 (da) * 2014-04-25 2019-05-06 Pf Medicament Igf-1r-antistof-lægemiddel-konjugat og dens anvendelse til behandling af kræft
JP6968790B2 (ja) 2015-10-26 2021-11-17 ピエール、ファーブル、メディカマン Ｉｇｆ−１ｒ発現癌の処置のための組成物
JP7183163B2 (ja) * 2017-01-06 2022-12-05 クレシェンド・バイオロジックス・リミテッド プログラム細胞死（ｐｄ－１）に対するシングルドメイン抗体
KR20200083574A (ko) 2017-11-13 2020-07-08 크레센도 바이오로직스 리미티드 Cd137 및 psma에 결합하는 분자
GB201802573D0 (en) 2018-02-16 2018-04-04 Crescendo Biologics Ltd Therapeutic molecules that bind to LAG3
BR112021000934A2 (pt) 2018-07-20 2021-04-27 Pierre Fabre Medicament receptor para vista
MX2021003295A (es) 2018-09-27 2021-07-16 Pf Medicament Enlazadores basados en sulfomaleimida y sus correspondientes conjugados.
JP2022512716A (ja) * 2018-10-19 2022-02-07 メドイミューン・リミテッド ピロロベンゾジアゼピン複合体
KR20220088847A (ko) 2019-09-04 2022-06-28 주식회사 와이바이오로직스 항-vsig4 항체 또는 항원-결합 단편 및 이들의 용도
EP4353220A1 (fr) 2022-10-12 2024-04-17 Pierre Fabre Medicament Utilisation d'une composition aqueuse liquide pour la solubilisation et la stabilisation d'un conjugué anticorps-médicament
WO2024206858A1 (fr) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions pour induire une hydrolyse de ras gtp et leurs utilisations

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US5079233A (en) 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
FR2661000B1 (fr) 1990-04-12 1992-08-07 Aerospatiale Machine d'essais d'eprouvettes en cisaillement.
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5561427A (en) 1994-12-30 1996-10-01 Psc Inc. Analog to digital converter with continuous conversion cycles and large input signal range
FR2873699B1 (fr) * 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
NZ553500A (en) 2004-09-23 2009-11-27 Genentech Inc Genentech Inc Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain a free cysteine amino acid in the heavy chain
FR2888850B1 (fr) * 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
AU2007245164A1 (en) * 2006-03-28 2007-11-08 Biogen Idec Ma Inc. Anti-IGF-IR antibodies and uses thereof
TW200833711A (en) * 2006-12-22 2008-08-16 Genentech Inc Antibodies to insulin-like growth factor receptor
WO2008141044A2 (fr) 2007-05-08 2008-11-20 Genentech, Inc. Anticorps anti-muc16 produits avec de la cystéine et conjugués anticorps-médicament
US8937161B2 (en) 2007-10-19 2015-01-20 Genentech, Inc. Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates
AR080793A1 (es) * 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
JP5972864B2 (ja) 2010-04-15 2016-08-17 メディミューン リミテッド ピロロベンゾジアゼピン及びそれらのコンジュゲート
WO2012145507A2 (fr) * 2011-04-19 2012-10-26 Merrimack Pharmaceuticals, Inc. Anticorps anti-igf-1r et anti-erbb3 monospécifiques et bispécifiques

Also Published As

Publication number Publication date
EP3134438B1 (fr) 2020-09-30
IL274226A (en) 2020-06-30
EP3783033A1 (fr) 2021-02-24
MX2016014000A (es) 2017-05-30
JP2017513898A (ja) 2017-06-01
SA516380131B1 (ar) 2019-12-04
PT3134438T (pt) 2020-12-31
PL3134438T3 (pl) 2021-04-06
WO2015162292A1 (fr) 2015-10-29
LT3134438T (lt) 2021-01-11
RS61379B1 (sr) 2021-02-26
CN106459204A (zh) 2017-02-22
CA2946795A1 (fr) 2015-10-29
TN2016000445A1 (en) 2018-04-04
HUE052223T2 (hu) 2021-04-28
AU2015250760B2 (en) 2020-10-22
RU2016145277A (ru) 2018-05-28
JP2021073279A (ja) 2021-05-13
JP6835591B2 (ja) 2021-02-24
MY182444A (en) 2021-01-25
ZA201607095B (en) 2020-07-29
SI3134438T1 (sl) 2021-04-30
ES2841249T3 (es) 2021-07-07
BR112016024575B1 (pt) 2024-02-27
MX2021002144A (es) 2021-03-09
KR102357032B1 (ko) 2022-02-08
JP7191134B2 (ja) 2022-12-16
UA122390C2 (uk) 2020-11-10
MA39378A1 (fr) 2018-05-31
KR20220018620A (ko) 2022-02-15
US11365259B2 (en) 2022-06-21
RU2016145277A3 (fr) 2018-12-13
HRP20202047T1 (hr) 2021-02-19
EP3134438A1 (fr) 2017-03-01
IL248357B (en) 2020-05-31
AU2015250760A1 (en) 2016-11-03
CN112851808A (zh) 2021-05-28
US10202458B2 (en) 2019-02-12
KR20160145110A (ko) 2016-12-19
US20190330353A1 (en) 2019-10-31
MA53069A1 (fr) 2021-10-29
KR20200128210A (ko) 2020-11-11
NZ725423A (en) 2023-07-28
AU2015250760C1 (en) 2023-11-16
DK3134438T3 (da) 2020-12-07
KR102177436B1 (ko) 2020-11-12
IL248357A0 (en) 2016-11-30
CA2946795C (fr) 2021-03-30
RU2698977C2 (ru) 2019-09-02
MA39378B2 (fr) 2021-02-26
CN106459204B (zh) 2021-02-02
BR112016024575A2 (pt) 2017-10-10
CY1123743T1 (el) 2022-03-24
US20170267766A1 (en) 2017-09-21

Similar Documents

Publication Publication Date Title
MA53069B1 (fr) Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer
MA35659B1 (fr) Protéine de liaison à un antigène et son utilisation comme produit d'adressage pour le traitement du cancer
MA40476B1 (fr) Anticorps et fragments de fixation à l'antigène anti-lag3
MA49599A1 (fr) Anticorps spécifiques à cd47 et pd-l1
CY1124791T1 (el) Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων
MA47313A (fr) Formulations sous-cutanées d'anticorps her2
PH12019500270A1 (en) Combination therapy for cancer
ZA201904218B (en) Anti¿ccr7 antibody drug conjugates
MA45029B1 (fr) Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer
BR112017025080A2 (pt) composto conjugado de fármaco com anticorpo anti-cd123, composição conjugada de fármaco com anticorpo, método de tratamento de um paciente que tem um câncer que expressa cd123, composição farmacêutica, e, anticorpo intacto ou fragmento de ligação de antígeno
MA39909B1 (fr) Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
MA42542B1 (fr) Molécules se liant à pd-1 et méthodes d'utilisation correspondantes
MA40913A (fr) Conjugués anticorps-médicament
MA40801A1 (fr) Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123
UA114891C2 (uk) ІЗОЛЬОВАНЕ АНТИТІЛО ЛЮДИНИ, ЯКЕ СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З АНГІОПОЕТИНПОДІБНИМ БІЛКОМ 3 ЛЮДИНИ (hАNGPTL3), ТА ЙОГО ЗАСТОСУВАННЯ
EA201992526A1 (ru) Стабильные составы анти-ctla4 антител, отдельно и в комбинации с антителами против рецептора 1 программируемой смерти (pd-1), и способы их применения
MA38396A1 (fr) Anticorps medicamenteux conjugues et leurs compositions pharmaceutiques pour traiter un cancer positif a ckit
MA44334A (fr) Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
MA33470B1 (fr) Polythérapie à base d'un anticorps afucosylé anti-cd20 et de fludarabine et/ou mitoxantrone
BR112019023909A8 (pt) Uso de um imunoconjugado que se liga a folr1, e, uso de um imunoconjugado que se liga a folr1 e pembrolizumab
EP4282434A3 (fr) Anticorps, leurs utilisations et leurs conjugués
MA38161A1 (fr) Anticorps anti-bmp-6
MX2020010104A (es) Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado.
PH12020551556A1 (en) Drug conjugates of cmet monoclonal binding agents, and uses thereof